Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease-Current Background, Hopes, and Perspectives.
第二型糖尿病患者和非酒精性脂肪肝病患者中的葡萄糖樣肽-1受體激動劑-現況、希望和展望。
Metabolites 2023-05-29
Does Therapy with Glucagon-like Peptide 1 Receptor Agonists Have an Effect on Biochemical Markers of Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)? Pleiotropic Metabolic Effect of Novel Antidiabetic Drugs in Patients with Diabetes-Interventional Study.
胰高血糖素樣肽-1受體激動劑治療對代謝異常相關脂肪肝疾病(MASLD)的生化標誌是否有影響?新型抗糖尿病藥物對糖尿病患者的多效代謝影響:干預性研究。
Pharmaceuticals (Basel) 2023-11-02
The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease.
糖尿病樣胰高血糖素-1受體激動劑在非酒精性脂肪肝病中的作用。
Expert Rev Clin Pharmacol 2024-01-31
The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.
胰高血糖素樣肽-1受體激動劑在治療代謝異常相關脂肪肝疾病中的新興角色。
Clin Gastroenterol Hepatol 2024-03-20
The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis.
葡萄糖樣肽-1 受體激動劑在代謝功能障礙相關脂肪肝炎中的作用。
Diabetes Obes Metab 2024-05-08
Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: Opportunities and challenges.
胰高血糖素和葡萄糖素受體激動劑在代謝功能障礙相關的脂肪肝疾病中的作用:機會與挑戰。
World J Hepatol 2024-05-31